Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
2.70
Nov 13 • 3:59 PM ET Dollar change-0.14 Percentage change(-4.93%)
Aftermarket Close
2.70
Aftermarket • 7:56 PM ET Dollar change0.00 Percentage change(0.00%)
Index
-
Market Cap
2.22M
Enterprise Value
-11.76M
Income
-6.17M
Sales
35.37M
Book/sh
102.85
Cash/sh
17.78
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
50
IPO
Oct 30, 2009
P/E
-
Forward P/E
-
PEG
-
P/S
0.06
P/B
0.03
P/C
0.15
P/FCF
-
EV/EBITDA
-
EV/Sales
-0.33
Quick Ratio
4.03
Current Ratio
6.47
Debt/Eq
0.02
LT Debt/Eq
0.02
Option/Short
No / Yes
EPS (ttm)
-170.92
EPS next Y
-8.00
EPS next Q
-3.40
EPS this Y
86.46%
EPS next Y
79.49%
EPS next 5Y
-
EPS past 3/5Y
92.58% 80.76%
Sales past 3/5Y
102.91% 247.73%
EPS Y/Y TTM
54.07%
Sales Y/Y TTM
-5.23%
EPS Q/Q
86.59%
Sales Q/Q
0.27%
Insider Own
-
Insider Trans
-
Inst Own
7.86%
Inst Trans
-
ROA
-18.89%
ROE
-23.37%
ROIC
-21.24%
Gross Margin
29.43%
Oper. Margin
-16.84%
Profit Margin
-17.45%
SMA20
-13.45%
SMA50
-73.14%
SMA200
-97.21%
Trades
Shs Outstand
0.28M
Shs Float
0.17M
52W High
464.00 -99.42%
52W Low
2.53 6.72%
Volatility
6.25% 13.12%
ATR (14)
0.89
RSI (14)
28.73
Beta
1.52
Rel Volume
0.11
Avg Volume
295.90K
Volume
32,106
Perf Week
-0.37%
Perf Month
-41.30%
Perf Quarter
-87.95%
Perf Half Y
-95.25%
Perf YTD
-98.90%
Perf Year
-99.19%
Perf 3Y
-100.00%
Perf 5Y
-100.00%
Perf 10Y
-100.00%
Prev Close
2.84
Price
2.70
Change %
-4.93%
Sunshine Biopharma, Inc. is a pharmaceutical company, which engages in the research, development, and commercialization of oncology and antiviral drugs. It is also involved in the development and commercialization of science-based nutritional supplements. The firm's product includes treatment for Coronavirus infections and anticancer drugs. The company was founded on August 31, 2006 and is headquartered in Fort Lauderdale, FL.
ChairmanDr. Steve N. Slilaty Ph.D.
CFOMr. Camille Sebaaly
Chief Commercial OfficerMr. Michel Roy
President of Sunshine Bio Investments IncMr. Robert G. Ferreira